Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 272,980 shares of the medical research company’s stock after selling 640 shares during the quarter. Primecap Management Co. CA’s holdings in Charles River Laboratories International were worth $50,392,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Cibc World Markets Corp boosted its stake in Charles River Laboratories International by 16.1% in the fourth quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company’s stock valued at $1,493,000 after acquiring an additional 1,124 shares during the period. Hilton Capital Management LLC boosted its position in shares of Charles River Laboratories International by 5.0% during the fourth quarter. Hilton Capital Management LLC now owns 8,038 shares of the medical research company’s stock worth $1,484,000 after buying an additional 380 shares during the period. Impact Capital Partners LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $422,000. Truvestments Capital LLC boosted its position in shares of Charles River Laboratories International by 6.4% during the fourth quarter. Truvestments Capital LLC now owns 2,562 shares of the medical research company’s stock worth $473,000 after buying an additional 155 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Charles River Laboratories International by 10.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,673 shares of the medical research company’s stock worth $309,000 after buying an additional 155 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Up 1.1 %

Charles River Laboratories International stock opened at $177.02 on Wednesday. The stock has a market cap of $9.05 billion, a P/E ratio of 1,180.13, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $274.77. The company’s fifty day simple moving average is $167.21 and its 200-day simple moving average is $184.18. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.46 earnings per share. As a group, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CRL has been the topic of several recent analyst reports. UBS Group reissued a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Citigroup raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and upped their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group cut their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and a consensus target price of $191.31.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).